Multiple Sclerosis Clinical Trials in New York

Showing 161-180 of 812 trials

Ulixertinib in People With Histiocytic Neoplasms

NCT06411821

The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.

Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center38 participantsStarted May 2024

Rochester, Minnesota, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma

Merck Sharp & Dohme LLC738 participantsStarted Oct 2018

Los Angeles, California, United States • Monterey, California, United States • Orange, California, United States +189 more locations

Ulixertinib in People With Histiocytic Neoplasms

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Multiple Sclerosis Trials in Other Cities

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Expressive Helping for Chinese-Speaking Cancer Patients and Survivors

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS)

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Other Conditions in New York